Why is the Immutep (ASX:IMM) share price dipping today?

The Immutep (ASX:IMM) share price slipped today after the company posted an update about one of its clinical trials. Here’s what we found out.
The post Why is the Immutep (ASX:IMM) share price dipping today? appeared first on The Motley Fool Australia. –

A doctor or medical expert in COVID protection adjusts her glasses, indicating growth or strong share price movement in ASX medical, biotech and health companies

The Immutep Ltd (ASX: IMM) share price is down 1.59% at the time of writing trading at 31 cents a share. This follows this morning’s announcement that Immutep is expanding Part B of its cancer treatment clinical trial.

Let’s break down what that means and why it could be moving the Immutep share price today.

More patients recruited for expanded trial

Based in Australia, Immutep develops novel immunotherapy treatments for cancer and autoimmune disease.

In today’s release, the biotechnology company advised that it had recruited 13 more patients with second-line non-small cell lung cancer (NSCLC) for Stage 1 of the now expanded Part B of its TACTI-002 Phase II trial.

The trial extension follows the recommendation of the data monitoring committee following a preliminary safety and efficacy review. TACTI-002 stands for Two ACTive Immunotherapies. 

Immutep is conducting the trial by treating cancer patients with a combination of its eftilagimod alpha product (efti) and Keytruda®, produced by US pharmaceutical company Merck & Co., Inc (NYSE: MRK).

Efti is in clinical development to treat cancer. Immutep has three additional treatments for cancer and autoimmune disease that also are in clinical development.

Immutep’s half-year update

Discussing the company’s leading efti product in its latest half-year FY21 results, Immutep advised:

Following the encouraging clinical results announced for efti last year, Immutep is in a very robust financial and operational position.

The company has increasing confidence in efti and accordingly, three new efti trials or trial extensions with up to 386 patients in different cancer indications were announced or started during the half year, in addition to its ongoing clinical trials of the product candidate.

Immutep is also working on scaling up efti manufacturing in preparation for potential commercial manufacturing and additional registration trials in multiple indications.

Immutep share price snapshot

Despite positive progress on its clinical trials, the Immutep share price has taken a 20.3% dive over the past month. Year-to-date, it’s fallen 24.1%.

The company presently has a market capitalisation of 217.3 million and there are 648.7 million shares outstanding.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Motley Fool contributor Gretchen Kennedy has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post Why is the Immutep (ASX:IMM) share price dipping today? appeared first on The Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;

To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.

An active and funded account with a positive trading balance is required to continue to have access to the tools;

Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;

Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!